LONDON --(BUSINESS WIRE)--Sep. 18, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA ® System in a patient enrolled in the A uto n omic Regulation Th erapy to E nhance M yocardial Function and Reduce...Read More

Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve LONDON --(BUSINESS WIRE)--Sep. 10, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for...Read More

Analysis finds overall cost savings far exceed system-related costs LONDON --(BUSINESS WIRE)--Sep. 4, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that a new cost analysis found the Company’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System...Read More

LONDON --(BUSINESS WIRE)--Aug. 22, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer of LivaNova , will present at the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, Sept....Read More

Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes LONDON --(BUSINESS WIRE)--Aug. 6, 2018-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology company, today announced the conclusion of the PRELUDE feasibility study for its Caisson Transcatheter...Read More

LONDON --(BUSINESS WIRE)--Aug. 1, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2018. For the second quarter of 2018, worldwide sales from continuing operations were $287.5 million , an increase...Read More

LONDON --(BUSINESS WIRE)--Jul. 3, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More

LONDON --(BUSINESS WIRE)--Jun. 14, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received FDA 510(k) clearance for its MEMO 4D ® semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device.

...Read More

LONDON --(BUSINESS WIRE)--Jun. 13, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced that William A. Kozy , retired Executive Vice President and Chief Operating Officer at Becton, Dickinson and Company

...Read More

LONDON --(BUSINESS WIRE)--Jun. 11, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare has approved the Company’s Perceval ® sutureless aortic heart valve to treat aortic

...Read More

LONDON --(BUSINESS WIRE)--May 31, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences. Chief Executive Officer Damien McDonald and Chief Financial Officer

...Read More

LONDON --(BUSINESS WIRE)--May 30, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today issued a statement in regard to the U.S. Centers for Medicare & Medicaid Services’ (“CMS”) publication of a tracking sheet to reconsider its National

...Read More

LONDON --(BUSINESS WIRE)--May 2, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2018. For the first quarter of 2018, worldwide sales from continuing operations were...Read More

LONDON --(BUSINESS WIRE)--Apr. 30, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has successfully completed the divestiture of its Cardiac Rhythm Management (“CRM”) business to MicroPort Scientific Corporation (HK:...Read More

LivaNova celebrates cardiac perfusion milestone, surpassing one million worldwide clinical cases LONDON --(BUSINESS WIRE)--Apr. 26, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Inspire® innovative adult oxygenator...Read More

LONDON --(BUSINESS WIRE)--Apr. 17, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received CE Mark for its Vagus Nerve Stimulation Therapy ® (“VNS Therapy”) System comprised of the SenTiva ® generator and...Read More

LONDON --(BUSINESS WIRE)--Apr. 5, 2018-- LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology company, will host a conference call to discuss its first quarter 2018 results on Wednesday, May 2, 2018 at 2 p.m. London time (9 a.m. Eastern Daylight Time)....Read More

LONDON --(BUSINESS WIRE)--Apr. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it closed its acquisition of TandemLife. Previously, on Feb. 14 , LivaNova announced its intent to acquire TandemLife, a privately held...Read More

LONDON --(BUSINESS WIRE)--Mar. 29, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has received CE Mark approval for its Bicarbon ® aortic valves for use with low-dose anticoagulant therapy....Read More

LONDON --(BUSINESS WIRE)--Mar. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the first patient in a clinical study to examine the use of LivaNova’s new Microburst Vagus Nerve Stimulation...Read More

Pre-market trial to demonstrate safety and effectiveness of Perceval sutureless aortic heart valve LONDON --(BUSINESS WIRE)--Mar. 22, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has announced the first patient enrollment in the...Read More

LONDON --(BUSINESS WIRE)--Mar. 20, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer of LivaNova , will present at the Needham & Company Healthcare Conference in New York on Tuesday,...Read More

LONDON --(BUSINESS WIRE)--Mar. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation...Read More

LONDON --(BUSINESS WIRE)--Feb. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2017. For the fourth quarter of 2017, worldwide sales from...Read More

LONDON --(BUSINESS WIRE)--Feb. 15, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences taking place on Tuesday, March 13 ....Read More

Company will add advanced cardiopulmonary temporary support solutions to its portfolio LONDON --(BUSINESS WIRE)--Feb. 14, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire...Read More

Company celebrates new design that delivers improved flexibility, clarity and control LONDON --(BUSINESS WIRE)--Feb. 1, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has achieved CE Mark for its new PureFlex TM line...Read More

LONDON --(BUSINESS WIRE)--Jan. 24, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2017 results on Wednesday, Feb. 28, 2018 at 8 a.m. CST ( 2 p.m. GMT )....Read More

Company is advancing clinical research with three aortic valve studies LONDON --(BUSINESS WIRE)--Jan. 11, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that the first patient has been enrolled in the Be havior of Valve...Read More

LONDON --(BUSINESS WIRE)--Jan. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Matthew J. Dodds has joined the Company as Senior Vice President, Corporate Development. In this role, Dodds is responsible for Business...Read More

First patient enrolled to assess the effectiveness and efficiency of VNS Therapy as adjunctive treatment LONDON --(BUSINESS WIRE)--Jan. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the...Read More